India's Dr Reddy's posts worst week in 3 years as semaglutide setback stokes growth fears

Dr Reddy's extends slide as semaglutide setback threatens first-mover edge

Supply disruption has cast doubt on Dr Reddy's ability to capitalise on its early lead, with brokerages warning that prolonged delay could a

Dr Reddy’s delays Semaglutide supplies after API quality issue

Dr Reddy’s said patient safety and global regulatory filings remain unaffected as it investigates the issue.

Dr Reddy's delays semaglutide supply due to active ingredient issue

The drugmaker said certain batches of semaglutide were found to be out ​of specification and ‌that it is investigating the root cause and ta

DRL’s semaglutide supply hits a stumbling block, affects other companies too

The company’s management told analysts that there was a process-linked issue during scaling up, affecting future supplies in the country and

Demand for GLP-1 weight-loss and diabetes drugs plateaus, says industry tracker

A total of 31 generic semaglutide brands contributed to 82 per cent of the unit sales of the month

Dr Reddy’s pauses weight loss drug on quality fears